The therapeutic effect of ofatumumab in autoimmune encephalitis: A case series

The management of autoimmune encephalitis (AE) with immunotherapy is non-standardized, especially in refractory AE. Ofatumumab (OFA), an anti-CD20 antibody, has not been reported in the treatment of AE. This study presented three AE cases that received the OFA treatment. OFA was administered subcutaneously at a dose of 20 mg two or three times within three weeks. There were some mild adverse effects, including low-grade fever and dizziness. They had favorable responses (reduced antibody titer and clinical symptom improvement). Their symptoms were stable and even improved during a three-month follow-up. Thus, OFA injection is demonstrated to be safe and effective in treating AE. This is the first report about OFA treatment in AE, depicting its potential as a therapeutic option.

Automated summary

This study presents three cases of autoimmune encephalitis (AE) treated with ofatumumab (OFA), an anti-CD20 antibody. OFA was administered subcutaneously at a dose of 20 mg two or three times within three weeks. The patients had mild adverse effects but showed favorable responses with reduced antibody titer and clinical symptom improvement. During a three-month follow-up, their symptoms remained stable or even improved. OFA injection is demonstrated to be a safe and effective therapeutic option for treating AE.